Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Xenon Pharmaceuticals Inc’s stock clocked out at $39.3, up 1.52% from its previous closing price of $38.71. In other words, the price has increased by $1.52 from its previous closing price. On the day, 0.62 million shares were traded. XENE stock price reached its highest trading level at $39.6 during the session, while it also had its lowest trading level at $38.585.
Ratios:
To gain a deeper understanding of XENE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.14 and its Current Ratio is at 15.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on May 07, 2025, initiated with a Buy rating and assigned the stock a target price of $55.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 05 ’25 when GANNON STEVEN sold 3 shares for $30.48 per share. The transaction valued at 91 led to the insider holds 7,141 shares of the business.
MORTIMER IAN sold 22,468 shares of XENE for $903,214 on Jan 24 ’25. The PRESIDENT & CEO now owns 31,302 shares after completing the transaction at $40.20 per share. On Jan 27 ’25, another insider, MORTIMER IAN, who serves as the PRESIDENT & CEO of the company, sold 16,315 shares for $40.50 each. As a result, the insider received 660,806 and left with 31,302 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3030257920 and an Enterprise Value of 2551427840. For the stock, the TTM Price-to-Sale (P/S) ratio is 404.04 while its Price-to-Book (P/B) ratio in mrq is 4.77. Its current Enterprise Value per Revenue stands at 340.19 whereas that against EBITDA is -8.087.
Stock Price History:
The Beta on a monthly basis for XENE is 1.17, which has changed by -0.030826151 over the last 52 weeks, in comparison to a change of 0.16222072 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is 15.96%, while the 200-Day Moving Average is calculated to be 9.36%.
Shares Statistics:
It appears that XENE traded 1.10M shares on average per day over the past three months and 622780 shares per day over the past ten days. A total of 76.94M shares are outstanding, with a floating share count of 74.01M. Insiders hold about 4.01% of the company’s shares, while institutions hold 104.41% stake in the company. Shares short for XENE as of 1755216000 were 6892652 with a Short Ratio of 6.24, compared to 1752537600 on 6505144. Therefore, it implies a Short% of Shares Outstanding of 6892652 and a Short% of Float of 9.9700004.
Earnings Estimates
The dynamic stock of Xenon Pharmaceuticals Inc (XENE) is currently being evaluated by a team of 13.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$1.23, with high estimates of -$0.97 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$3.85 and -$4.72 for the fiscal current year, implying an average EPS of -$4.29. EPS for the following year is -$4.57, with 14.0 analysts recommending between -$2.15 and -$5.4.
